A Phase 3 interventional study of roflumilast cream 0.3% and Zoryve in Plaque Psoriasis, sponsored by Padagis LLC. Completed at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.
Among the 17 studies testing roflumilast in Psoriasis, this one is the 3rd largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 13th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Modern Research Associates, PLLC · Sites in United States
Ahmed Ibrahim · Sites in Egypt
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 416 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 46 across the 17 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 9 most frequent:
Padagis LLC is the lead sponsor of 37 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Padagis LLC has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
1 of the studies testing roflumilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725822Modern Research Associates, PLLCAn Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing roflumilast in Psoriasis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the safety and efficacy of Padagis' product to an FDA approved product for the treatment of plaque psoriasis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: roflumilast cream 0.3%
Drug: Zoryve
Drug: Placebo
test product
Reference Listed Drug product
placebo
Investigator's Global Assessment (IGA)
percentage of subjects at Day 56 who achieve Treatment Success, which is defined as an IGA score of None (0) or Minimal (1) with a 2-grade improvement from Day 1
Time frame: Day 1 to Day 56
| Milestone | Padagis Active Product | Reference Product | Padagis Placebo Product |
|---|---|---|---|
| Started | 169 | 166 | 81 |
| Completed | 154 | 155 | 75 |
| Not completed | 15 | 11 | 6 |
percentage of subjects at Day 56 who achieve Treatment Success, which is defined as an IGA score of None (0) or Minimal (1) with a 2-grade improvement from Day 1
| Participants | Padagis Active Product | Reference Product | Padagis Placebo Product |
|---|---|---|---|
| Investigator's Global Assessment (IGA) | 78 | 79 | 22 |
Collected over Day 1 to 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Padagis Active Product | 0/169 (0%) | 0/169 (0%) | 0/169 (0%) |
| Reference Product | 0/166 (0%) | 0/166 (0%) | 0/166 (0%) |
| Padagis Placebo Product | 0/81 (0%) | 0/81 (0%) | 0/81 (0%) |
| Age, Continuous(years) | Padagis Active Product | Reference Product | Padagis Placebo Product | Total |
|---|---|---|---|---|
| Mean | 50.3 ± 13.8 | 49.0 ± 13.9 | 48.8 ± 13.2 | 49.3 ± 13.6 |
| Sex: Female, Male(Participants) | Padagis Active Product | Reference Product | Padagis Placebo Product | Total |
|---|---|---|---|---|
| Female | 77 | 66 | 34 | 177 |
| Male | 92 | 100 | 47 | 239 |
| Race (NIH/OMB)(Participants) | Padagis Active Product | Reference Product | Padagis Placebo Product | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 2 |
| Asian | 5 | 3 | 2 | 10 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 2 |
| Black or African American | 32 | 32 | 14 | 78 |
| White | 129 | 123 | 61 | 313 |
| More than one race | 1 | 1 | 1 | 3 |
| Unknown or Not Reported | 1 | 4 | 3 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Padagis Active Product | Reference Product | Padagis Placebo Product | Total |
|---|---|---|---|---|
| Hispanic or Latino | 98 | 98 | 50 | 246 |
| Not Hispanic or Latino | 71 | 68 | 31 | 170 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2023 to primary completion in Aug 2023, 6 months.
Results were first posted in Aug 2026, 3 years after primary completion. A results delay was requested in Aug 2024.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 6 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast